HBsAgÓпÉÄÜÏûʧÂð

·¢²¼£º2017-09-06¡¡|¡¡À´Ô´£º²Ìð©¶«Ò½Éú×ÔýÌå¡¡|¡¡ä¯ÀÀ£º12499

2017ÄêÅ·Ö޸β¡Ñ§»á·¢²¼µÄ¡¶ÂýÐÔHBV¸ÐȾ¹ÜÀíÁÙ´²Êµ¼ùÖ¸ÄÏ¡·[2]ÖÐÌá³ö£¬ºËÜÕ(Ëá)ÀàÒ©ÎïÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×ÀíÏëµÄÖÎÁÆÖÕµãÊÇ¡°È·Ö¤ÎªHBsAgÏûʧ(ÓлòÎÞ¿¹HBsѪÇåת»»)¡±¡£ÄÇô£¬HBsAgÓпÉÄÜÏûʧÂð£¿

ÎÒÃÇÏÈ¿´¿´HBsAgÔÚÒҸβ¡¶¾¸ÐȾÖÐÆðµÄ×÷Óá£ÒҸβ¡¶¾ÊÇÒ»ÖÖÌØ±ð»á¡°×öÒ·þ¡±µÄ²¡¶¾¡£ÔÚÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕßµÄѪÇåÖУ¬²¡¶¾¿ÅÁ£¿É¸ß´ï10µÄ13´Î·½¿½±´/ºÁÉý£¬ÆäÖÐÍêÕûµÄ(³ÉÊìµÄ)ÒÒÐ͸ÎÑײ¡¶¾¿ÅÁ£½öÕ¼Íò·ÖÖ®Ò»£¬Ö»ÓÐÉÙÊýÊǾßÓÐÈ«»ùÒòµÄ¡¢Óд«È¾ÐԵIJ¡¶¾¿ÅÁ£¡£Ã¿¸öÒҸβ¡¶¾Ö»ÐèÒªÔ¼100¸öHBsAg·Ö×Ó×÷ΪËüµÄÍâĤµ°°×£¬µ«ÊÇÔÚÒҸβ¡¶¾¸´Öƹý³ÌÖвúÉúµÄHBsAgµÄÊýÁ¿±È²¡¶¾×°ÅäËùÐè´óÔ¼¶à³öÁË10Íò¡«100Íò±¶£¬Êý°ÙÍò¶àÓàµÄHBsAg·Ö×ÓÔÚѪҺÖÐÑ­»·¡£HBsAg²»½ö¿ÉÒÔ×ö²¡¶¾µÄ¡°ÍâÒ¡±£¬Ëü»¹»á×÷ÓÃÓÚÈËÌåµÄÃâÒßϸ°û£¬Ó°Ïì»úÌåÃâÒßϵͳ£¬×è°­ÒҸβ¡¶¾µÄÇå³ý¡£´ËÍ⣬HBsAg¿É×÷ÓÃÓÚTϸ°û£¬Ê¹ÆäʧȥɱÉ˱»HBV¸ÐȾµÄ¸Îϸ°ûµÄÄÜÁ¦£»¶øHBsAg×÷ÓÃÓÚBϸ°û»áÓ°ÏìÒҸβ¡¶¾¿¹ÌåµÄ²úÉú¡£HBsAgµÄ³ÖÐø´æÔÚʹHBV¸ÐȾÂýÐÔ»¯£¬Òò´Ë£¬HBsAgˮƽԽµÍ£¬²¡¶¾ÔÚÌåÄڵĸù»ù¾ÍÔ½²»Àο¿£¬Çå³ýÆðÀ´Ò²»áÏà¶ÔÈÝÒס£

¸Îϸ°ûµÄÉúÃüÖÜÆÚ´óԼΪ100Ì죬ÿÌìÔ¼ÓÐ1%µÄ¸Îϸ°ûµòÍö£¬ÐµĸÎϸ°ûÔÙÉú£¬¶øÐµĸÎϸ°ûÍùÍùÊÇûÓб»ÒҸβ¡¶¾¸ÐȾµÄ¡°¸É¾»¡±Ï¸°û¡£Èç¹û³ÖÐøÊ¹Óÿ¹²¡¶¾Ò©ÎïÒÖÖÆÒҸβ¡¶¾¸´ÖÆ£¬¾ÉµÄ¸Îϸ°û(°üÀ¨ÕûºÏÁËHBV DNAµÄ¸Îϸ°û)Öð½¥µòÍö£¬ÐµÄδ±»²¡¶¾¸ÐȾµÄ¡°¸É¾»¡±¸Îϸ°û²»¶ÏÔÙÉú£¬³¤ÆÚ³ÖÐøÏÂÈ¥£¬HBsAgÊÇÓпÉÄÜÏûʧµÄ¡£

ÎÒ¹ų́ÍåµÄÒ½ÉúÔø¶Ô2121ÀýHBeAgÒõÐÔÂýÐÔHBV¸ÐȾÕß½øÐг¤ÆÚµÄËæ·Ã¡£ÕâЩ»¼ÕßÖÐ50.4%µÄÈËÔÚ28¡«75ËêÆÚ¼ä»á³öÏÖHBsAg×ÔÈ»Ïûʧ[3]£¬·ÖÎöÕâЩ»¼ÕßHBsAgµÄÓÐÀûÒòËØ£¬·¢ÏÖÒҸβ¡¶¾µÄC»ùÒòÐͱÈB»ùÒòÐ͸üÈÝÒ××Ô·¢ÐÔHBsAgÏûʧ¡£ÁíÍ⣬ÄÐÐÔ¡¢HBV DNA

ÔŲ́ÍåµÄÁíÒ»ÏîÑо¿ÖУ¬1991-1992ÄêµÇ¼ÇÄÉÈ볤ÆÚËæ·ÃÇÒHBsAgµÈÊý¾ÝÍêÕûµÄ2946ÀýÂýÐÔÒҸβ¡¶¾¸ÐȾÕßÔÚËæ·Ã48149.1ÈË-ÄêÆÚ¼ä£¬ÀÛ»ý18%µÄ»¼ÕßHBsAgÏûʧ[4]¡£ÎÒ¹úÏã¸ÛµÄÒ½Éú¶Ô775Àý³öÏÖHBeAgÏûʧµÄHBeAgÑôÐÔÂýÐÔHBV¸ÐȾÕßËæ·Ã1Äê¡¢5Äê¡¢10Äê¡¢15ºó¡¢20ÄêºÍ25Ä꣬HBsAgÏûʧÂÊ·Ö±ðΪ0.3%¡¢1.3%¡¢3.0%¡¢8.9%¡¢15.7%ºÍ23.6%[5]¡£


´ÓÕâЩÑо¿ÖпÉÒÔ¿´³ö£¬Òª´ïµ½HBsAgÏûʧ£¬ÏÈÒª´ïµ½e¿¹Ô­Ïûʧ¡¢ÑªÇåѧת»»ÒÔ¼°HBV DNA¸´ÖƵij¤ÆÚÒÖÖÆ¡£

²Î¿¼ÎÄÏ×£º

[1] ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á, ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á. ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2015Äê°æ£©. Öйú¸ÎÔಡÔÓÖ¾£¨µç×Ӱ棩. 2015. (3): 1-18.

[2] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.LID - S0168-8278(17)30185-X [pii]LID - 10.1016/j.jhep.2017.03.021 [doi]. J Hepatol. 2017 .

[3] Tseng TC, Liu CJ, Chen CL, et al. Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. Aliment Pharmacol Ther. 2015. 41(10): 949-60.

[4] Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014. 63(10): 1648-57.

[5] Fung J, Wong DK, Seto WK, Kopaniszen M, Lai CL, Yuen MF. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. Am J Gastroenterol. 2014. 109(11): 1764-70.

Ïà¹ØÐÂÎÅ


×ʸñÖ¤Êé±àºÅ£º(Ãö)-·Ç¾­ÓªÐÔ-2014-0006 2015 ¸£½¨ÒÚ²©µç¾ºµç¾º¹É·ÝÓÐÏÞ¹«Ë¾ ÃöICP±¸11026770ºÅ

Ãö¹«Íø°²±¸ 35092602000113ºÅ

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿